Small varieties of large demand, 10 billion contrast agent market continued to accelerate growth.

"Pharmaceutical Network Market Analysis" Recent data show that The application for generic generic seyl alcohol injection of Collum Pharmaceuticals was acceptedOnly Boreco, Italy, has been approved for import in the domestic market for the contrast agentUp to now, Collum Pharmaceuticals and subsidiaries have a contrast agent product in the review and approvalContrast agents, also known as contrast agents, are chemicals injected or taken into human tissues or organs to enhance the visual observation effectThe density of these products is higher or lower than that of the surrounding tissue situated with some instruments to display the imageSuch as line observation commonly used iodine preparations, sulphate, etcAccording to the National Basic Medical Insurance Drug Catalog, four sub-species, such as iodized ray contrast agent, non-iodized ray contrast agent, magnetic resonance imaging contrast agent and ultrasound contrast agent, are classified as contrast agentsAt present, with the progress of medical imaging, magnetic resonance imaging and the strengthening of imaging has gradually become an important means to examine human tissue organsAnd in the intervention of radiology to promote the domestic potential market demand has also surfacedAccording to the data, the global photocreator market size of US$100 million is expected to reach US$100 millionIn China's public hospitals, county-level public hospitals, urban community centers and township hospitals referred to as China's public medical institutions terminal contrast agent market size is also rapidly climbing year by year annual growth rate of 、、、 annual sales have climbed to 100 million yuanAccording to this growth rate is expected to exceed 100 million yuan in the year and will show a sustained growth trendHowever, it is worth noting that in the past, due to the high technical barriers of contrast agent products in the global market is mainly occupied by foreign companies such as Germany, the United States, France, Italy, the United States, Germany, Sweden, Japan, India and so onAnd the domestic enterprises are mainly Yangzijiang, Hengrui Pharmaceuticals, Beilu Pharmaceuticals and so onIn fact, compared with most of the pharmaceutical sub-sectors of the photo-creating agent industry is a small variety of original research manufacturers and imitation manufacturers are less and most product patents expired for many years still only the original research one or a small number of imitationBut it is also because of the overall pattern of good generic alternative space is large In recent years, more and more domestic enterprises have noticed that this market prospect is beginning to add code to the Bureau of Collum Pharmaceuticals is only one of the representatives At present, in addition to Collum Pharmaceuticals and its subsidiaries have a contrast agent products in the review and approval, there are a number of domestic enterprises in this field has a bright result Such as diazepam di sodium injection is Bayer's original research products in China's public medical institutions terminal sales of nearly 100 million yuan at present there is Zhengda Tianqing Pharmaceutical Group's class imitation approved; iodypaol injection is the top product annual sales of more than 100 million yuan currently obtained domestic approval of the enterprise has Shanghai Shitaili Pharmaceutical and Nanjing Zhengda Tianqing Pharmaceutical imitation in the new month, the month was approved and the same evaluation The industry believes that the coverage and frequency of testing, as well as population growth and the continued increase in tumor incidence and other factors in the future, China and other emerging markets are expected to further enhance the per capita drug use rate will further enhance the market growth rate will exceed the industry average growth rate more vigorous development